|
1
|
Veiga LH, Neta G, Aschebrook-Kilfoy B, Ron
E and Devesa SS: Thyroid cancer incidence patterns in Sao Paulo,
Brazil, and the US SEER Program, 1997–2008. Thyroid. 23:748–757.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vigneri R, Malandrino P and Vigneri P: The
changing epidemiology of thyroid cancer: Why is incidence
increasing? Curr Opin Oncol. 27:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sharma C: An analysis of trends of
incidence and cytohistological correlation of papillary carcinoma
of the thyroid gland with evaluation of discordant cases. J Cytol.
33:192–198. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cobin RH, Gharib H, Bergman DA, Clark OH,
Cooper DS, Daniels GH, Dickey RA, Duick DS, Garber JR, Hay ID, et
al: AACE/AAES medical/surgical guidelines for clinical practice:
Management of thyroid carcinoma. American Association of Clinical
Endocrinologists. American College of Endocrinology. Endocrine
practice: Official journal of the American College of Endocrinology
and the American Association of Clinical Endocrinologists.
7:202–220. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McLeod DS, Cooper DS, Ladenson PW, Ain KB,
Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, et
al: Prognosis of differentiated thyroid cancer in relation to serum
thyrotropin and thyroglobulin antibody status at time of diagnosis.
Thyroid. 24:35–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heider KH, Kuthan H, Stehle G and Munzert
G: CD44v6: A target for antibody-based cancer therapy. Cancer
Immunol Immunother. 53:567–579. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ahn SH, Henderson YC, Williams MD, Lai SY
and Clayman GL: Detection of thyroid cancer stem cells in papillary
thyroid carcinoma. J Clin Endocrinol Metab. 99:536–544. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iida J, Clancy R, Dorchak J, Somiari RI,
Somiari S, Cutler ML, Mural RJ and Shriver CD: DNA aptamers against
exon v10 of CD44 inhibit breast cancer cell migration. PLoS One.
9:e887122014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan W, Chen Y, Yao Y, Zhang H and Wang T:
Increased invasion and tumorigenicity capacity of CD44+/CD24-
breast cancer MCF7 cells in vitro and in nude mice. Cancer Cell
Int. 13:622013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Meng E, Long B, Sullivan P, McClellan S,
Finan MA, Reed E, Shevde L and Rocconi RP: CD44+/CD24- ovarian
cancer cells demonstrate cancer stem cell properties and correlate
to survival. Clin Exp Metastasis. 29:939–948. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Di Como CJ, Urist MJ, Babayan I, Drobnjak
M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A and Cordon-Cardo
C: p63 expression profiles in human normal and tumor tissues. Clin
Cancer Res. 8:494–501. 2002.PubMed/NCBI
|
|
12
|
Deyoung M and Ellisen L: p63 and p73 in
human cancer: Defining the network. Oncogene. 26:5169–5183. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Cho SJ and Chen X: RNPC1, an
RNA-binding protein and a target of the p53 family, regulates p63
expression through mRNA stability. Proc Natl Acad Sci USA.
107:9614–9619. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miyauchi A, Kudo T, Hirokawa M, Ito Y,
Kihara M, Higashiyama T, Yabuta T, Masuoka H, Shindo H, Kobayashi K
and Miya A: Ki-67 labeling index is a predictor of postoperative
persistent disease and cancer growth and a prognostic indicator in
papillary thyroid carcinoma. Eur Thyroid J. 2:57–64. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brown RL, Reinke LM, Damerow MS, Perez D,
Chodosh LA, Yang J and Cheng C: CD44 splice isoform switching in
human and mouse epithelium is essential for epithelial-mesenchymal
transition and breast cancer progression. J Clin Invest.
121:1064–1074. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sheridan C, Kishimoto H, Fuchs RK,
Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S and
Nakshatri H: CD44+/CD24- breast cancer cells exhibit enhanced
invasive properties: An early step necessary for metastasis. Breast
Cancer Res. 8:R592006. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang G, Zhang H, Wang J, Zhang Y, Xu H,
Wang C, Zhang H, Ma L, Li Q and Pang T: CD44 targets
Wnt/beta-catenin pathway to mediate the proliferation of K562
cells. Cancer Cell Int. 13:1172013. View Article : Google Scholar : PubMed/NCBI
|
